MEDP · Medpace Holdings, Inc.
$669.20
+2.33% last session
End-of-day data · close of 2026-10-23
Market cap
$19B
Enterprise value
$18B
Trailing P/E
37.2
Forward P/E
33.7
Dividend yield
0.0%
Beta
1.18
Avg volume
0M
Employees
7K
Daily Change %
2.33%
5 Days Change
5.74%
10 Days Change
7.23%
30 Days Change
5.96%
60 Days Change
5.47%
Month to Day Change
9.34%
Year to Day Change
16.44%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MEDP
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
UBS
Neutral$700
+4.6% vs priceBarclays
Equal-Weight$675
+0.9% vs priceRBC Capital
Outperform$692
+3.4% vs priceJefferies
Hold$515
-23.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | UBS | Maintains | Neutral | $673 → $700 |
| 2026-10-23 | Truist Securities | Maintains | Hold | $609 → $633 |
| 2026-10-23 | Barclays | Maintains | Equal-Weight | $625 → $675 |
| 2026-10-23 | TD Cowen | Maintains | Hold | $492 → $673 |
| 2026-10-07 | Mizuho | Maintains | Outperform | $665 → $700 |
| 2026-10-07 | Barclays | Maintains | Equal-Weight | $600 → $625 |
| 2026-09-30 | UBS | Upgrade | Sell → Neutral | $405 → $673 |
| 2026-07-24 | Mizuho | Maintains | Outperform | $586 → $665 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 68 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 9.4% above the 50-day MA ($611.40).
- bullish: Price vs 200-day MA: Trading 26.8% above the 200-day MA ($527.61).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+5.12) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($669.20).
MEDP Price Chart
Loading chart for MEDP…
Fundamentals
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.